Co-development of a school-based and primary care-based multicomponent intervention to improve HPV vaccine coverage amongst French adolescents (the PrevHPV Study).
co-construction
complex Intervention
eHealth tools
human papillomavirus
motivational interview
vaccination behaviours
Journal
Health expectations : an international journal of public participation in health care and health policy
ISSN: 1369-7625
Titre abrégé: Health Expect
Pays: England
ID NLM: 9815926
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
01
05
2023
received:
15
07
2022
accepted:
09
05
2023
medline:
11
9
2023
pubmed:
14
6
2023
entrez:
14
6
2023
Statut:
ppublish
Résumé
Despite various efforts to improve human papillomavirus (HPV) vaccine coverage in France, it has always been lower than in most other high-income countries. The health authorities launched in 2018 the national PrevHPV research programme to (1) co-develop with stakeholders and (2) evaluate the impact of a multicomponent complex intervention aimed at improving HPV vaccine coverage amongst French adolescents. To describe the development process of the PrevHPV intervention using the GUIDance for rEporting of intervention Development framework as a guide. To develop the intervention, we used findings from (1) published evidence on effective strategies to improve vaccination uptake and on theoretical frameworks of health behaviour change; (2) primary data on target populations' knowledge, beliefs, attitudes, preferences, behaviours and practices as well as the facilitators and barriers to HPV vaccination collected as part of the PrevHPV Programme and (3) the advice of working groups involving stakeholders in a participatory approach. We paid attention to developing an intervention that would maximise reach, adoption, implementation and maintenance in real-world contexts. We co-developed three components: (1) adolescents' and parents' education and motivation using eHealth tools (web conferences, videos, and a serious video game) and participatory learning at school; (2) general practitioners' e-learning training on HPV using motivational interviewing techniques and provision of a decision aid tool and (3) easier access to vaccination through vaccination days organised on participating middle schools' premises to propose free of charge initiation of the HPV vaccination. We co-developed a multicomponent intervention that addresses a range of barriers and enablers of HPV vaccination. The next step is to build on the results of its evaluation to refine it before scaling it up if proven efficient. If so, it will add to the small number of multicomponent interventions aimed at improving HPV vaccination worldwide. The public (adolescents, their parents, school staff and health professionals) participated in the needs assessment using a mixed methods approach. The public was also involved in the components' development process to generate ideas about potential activities/tools, critically revise the successive versions of the tools and provide advice about the intervention practicalities, feasibility and maintenance.
Identifiants
pubmed: 37312280
doi: 10.1111/hex.13778
pmc: PMC10485335
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1843-1853Informations de copyright
© 2023 The Authors. Health Expectations published by John Wiley & Sons Ltd.
Références
Vaccine. 2016 Feb 3;34(6):762-8
pubmed: 26752063
J Prim Care Community Health. 2017 Oct;8(4):349-362
pubmed: 29161946
BMJ Open. 2018 Apr 20;8(4):e019206
pubmed: 29678965
Am J Prev Med. 2019 Apr;56(4):591-602
pubmed: 30773231
Rev Epidemiol Sante Publique. 2013 Oct;61(5):447-54
pubmed: 24016739
JAMA Pediatr. 2018 May 7;172(5):e180016
pubmed: 29507952
J Pediatr Health Care. 2018 Mar - Apr;32(2):119-132
pubmed: 28918994
Vaccine. 2021 Jun 29;39(29):3916-3925
pubmed: 34088507
Wkly Epidemiol Rec. ;92(19):241-68
pubmed: 28530369
Health Technol Assess. 2021 Sep;25(57):1-132
pubmed: 34590577
Health Expect. 2023 Oct;26(5):1843-1853
pubmed: 37312280
BMJ Open. 2022 Mar 24;12(3):e057943
pubmed: 35332045
Cochrane Database Syst Rev. 2019 Nov 22;2019(11):
pubmed: 31755549
Bull Cancer. 2022 Apr;109(4):445-456
pubmed: 35168764
Clin Infect Dis. 2016 Aug 15;63(4):519-27
pubmed: 27230391
Vaccine. 2016 Aug 31;34(38):4478-4483
pubmed: 27498211
Vaccine. 2017 May 9;35(20):2676-2684
pubmed: 28408120
BMJ. 2008 Sep 29;337:a1655
pubmed: 18824488
BMJ Open. 2020 Apr 8;10(4):e033516
pubmed: 32273313
Hum Vaccin Immunother. 2019;15(7-8):1615-1627
pubmed: 30633623
Pharmacol Res. 2018 Jun;132:108-118
pubmed: 29665426
Vaccine. 2021 Jan 15;39(3):521-528
pubmed: 33328141
N Engl J Med. 2020 Oct 1;383(14):1340-1348
pubmed: 32997908
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
Lancet. 2021 Dec 4;398(10316):2084-2092
pubmed: 34741816
Pediatrics. 2016 Jul;138(1):
pubmed: 27296865
BMC Med Inform Decis Mak. 2013;13 Suppl 2:S2
pubmed: 24625093
Vaccine. 2015 Aug 14;33(34):4191-203
pubmed: 25896385
Drug Saf. 2018 Apr;41(4):329-346
pubmed: 29280070
Am J Public Health. 1999 Sep;89(9):1322-7
pubmed: 10474547
Exerc Sport Sci Rev. 2014 Apr;42(2):62-9
pubmed: 24508739
Expert Rev Vaccines. 2016;15(2):257-69
pubmed: 26559567
Prev Med. 2020 Feb;131:105968
pubmed: 31881235
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
Hum Vaccin Immunother. 2016 Jun 2;12(6):1566-88
pubmed: 26838959
BMJ Open. 2019 Aug 15;9(8):e029954
pubmed: 31420394
Vaccine. 2018 Dec 18;36(52):7923-7928
pubmed: 29983255
Lancet. 2019 Aug 10;394(10197):497-509
pubmed: 31255301
J Autoimmun. 2017 May;79:84-90
pubmed: 28190705
Patient Educ Couns. 2017 Jul;100(7):1280-1286
pubmed: 28209248
Vaccine. 2015 Nov 27;33 Suppl 4:D106-13
pubmed: 26615169
Hum Vaccin Immunother. 2022 Nov 30;18(5):2083894
pubmed: 35766886
Cochrane Database Syst Rev. 2018 May 09;5:CD009069
pubmed: 29740819
Prev Med. 2021 Mar;144:106399
pubmed: 33388322
Vaccine. 2020 Feb 5;38(6):1315-1331
pubmed: 31836255
BMJ. 2015 May 08;350:h2147
pubmed: 25956159
Euro Surveill. 2019 Sep;24(36):
pubmed: 31507265